Amaero (3DA) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
18 Jan, 2026Opening remarks and agenda
Meeting opened with confirmation of quorum, acknowledgment of board members, auditors, and share registry representatives, and was held on October 29, 2024.
Lucy Robb Wujek announced her resignation from the board, effective at the close of the AGM.
Virtual participation enabled via Zoom, with clear instructions for Q&A and voting.
Agenda included Chairman and CEO's presentation, formal business, and other business, with a focus on reviewing past milestones and outlining future plans.
Financial performance review
Fiscal year 2024 described as eventful, with significant progress and expectations for further milestones in 2025.
Reported first quarter with material revenue exceeding $1 million, including $600,000 from powder sales and $450,000 from PM HIP manufacturing.
Received approximately AUD 800,000 in government grant funding and $1.1 million in awards supporting the submarine industrial base.
Announced multiple capital raises: A$10M placement, A$20M institutional raise, and an upsized A$25M placement.
Guidance provided for scaling revenue in the back half of FY25, with EBITDA loss expected in line with FY24 and breakeven targeted for FY26.
Board and executive committee updates
Lucy Robb Wujek thanked for her service and confirmed not standing for re-election.
All non-executive directors, except Lucy Robb Wujek, stood for re-election; Alistair Cray nominated as a new director.
Eric Bono appointed as President & CTO.
Lieutenant General (ret.) H.R. McMaster joined as special advisor to the Chairman and CEO.
Latest events from Amaero
- Record revenue growth, strong backlog, and U.S. IPO plans mark a pivotal year.3DA
Q4 2026 TU - Poised for rapid growth, Amaero leads U.S. advanced powder production and targets a U.S. IPO.3DA
IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 - Shareholders and option holders strongly approved all proposed schemes and director option grants.3DA
Scheme Meeting 2026 presentation - Q3 FY2026 revenue up 301%–347% YoY, FY2026 fully contracted, U.S. redomiciliation advances.3DA
Q3 2026 TU - FY2025 saw record revenue, major supply deals, and facility expansion, setting up strong FY2026 growth.3DA
H2 2025 - Strategic U.S. shift, capital raises, and C103 supply deals set path to EBITDA breakeven by FY2026.3DA
H2 2024 - Revenue up 367%, net loss widens, FY2026 guidance cut amid U.S. contract delays.3DA
H1 2026 - Production and revenue scale rapidly with new atomizer, strong contracts, and U.S. market demand.3DA
Status Update - Seven resolutions, including share placements and a name change, were presented and voted online.3DA
EGM 2025